[
  {
    "ts": null,
    "headline": "Strength in Medical & Fluid Solutions Unit Drives Nordson: Can It Sustain?",
    "summary": "NDSN is gaining momentum as its Medical and Fluid Solutions segment delivers solid organic growth and margin expansion.",
    "url": "https://finnhub.io/api/news?id=4ec3710b079b14431937eaf56151e435a1b0c93348a213eea446a992206e1772",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767193680,
      "headline": "Strength in Medical & Fluid Solutions Unit Drives Nordson: Can It Sustain?",
      "id": 137950427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "NDSN is gaining momentum as its Medical and Fluid Solutions segment delivers solid organic growth and margin expansion.",
      "url": "https://finnhub.io/api/news?id=4ec3710b079b14431937eaf56151e435a1b0c93348a213eea446a992206e1772"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)",
    "summary": "Veracyte, Inc. (NASDAQ:VCYT) is among the 12 Best Genomics Stocks to Invest In. The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT) with an Underweight rating and a price target of $48, up from $40. According to the firm, the Life Science Tools and Diagnostics end markets are showing […]",
    "url": "https://finnhub.io/api/news?id=780401d67ea0f36a9e818f714708dd51948ddec4fe0e0e508f1506afd98d68af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767156500,
      "headline": "Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)",
      "id": 137950329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Veracyte, Inc. (NASDAQ:VCYT) is among the 12 Best Genomics Stocks to Invest In. The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT) with an Underweight rating and a price target of $48, up from $40. According to the firm, the Life Science Tools and Diagnostics end markets are showing […]",
      "url": "https://finnhub.io/api/news?id=780401d67ea0f36a9e818f714708dd51948ddec4fe0e0e508f1506afd98d68af"
    }
  }
]